1. Home
  2. BMY
  3. BMY News

Latest Bristol-Myers Squibb Company (BMY) News on November 19, 2024

Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
BMY

Business Wire

11 hours ago

Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms

Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
BMY

Benzinga

a day ago

Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases

BMY

MT Newswires

a day ago

Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $60 From $52, Maintains Equalweight

Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now?
BMY

Insider Monkey

a day ago

Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now?

EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer
BMY

Pharmaceutical Technology

2 days ago

EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer

BMY

Morningstar Research

2 days ago

Analyst Report: Bristol-Myers Squibb Company

Large Pension Doubled Palantir Stake, Bought Up Intel and CVS Stock
BMY

Barrons.com

3 days ago

Large Pension Doubled Palantir Stake, Bought Up Intel and CVS Stock

BMY

Morningstar Research

4 days ago

Analyst Report: Bristol-Myers Squibb Company

BMY

MT Newswires

4 days ago

HSBC Adjusts Bristol-Myers Squibb Price Target to $58 From $50, Maintains Hold Rating

BMY

MT Newswires

4 days ago

Bristol-Myers Says European Committee Recommends Approval of Opdivo-Yervoy Combination Therapy for Colorectal Cancer

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
BMY

Business Wire

4 days ago

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

BMY

MT Newswires

4 days ago

Bristol-Myers Says European Committee Recommends Approval of Repotrectinib

BMY

MT Newswires

4 days ago

Market Chatter: Bristol-Myers Squibb Faces $6.7 Billion Lawsuit in Renewed Cancer Drug Delay Case

Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
BMY

Business Wire

4 days ago

Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors

Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug
BMY

Reuters

5 days ago

Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug

Bristol-Myers Squibb Company's (NYSE:BMY) high institutional ownership speaks for itself as stock continues to impress, up 5.7% over last week
BMY

Simply Wall St.

5 days ago

Bristol-Myers Squibb Company's (NYSE:BMY) high institutional ownership speaks for itself as stock continues to impress, up 5.7% over last week

2 Beaten-Down Dividend Stocks to Buy and Hold
BMY

Motley Fool

5 days ago

2 Beaten-Down Dividend Stocks to Buy and Hold

Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
BMY

Investor's Business Daily

6 days ago

Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News

Is Bristol-Myers Squibb Company (BMY) Among The Top Dividend Contenders Right Now?
BMY

Insider Monkey

6 days ago

Is Bristol-Myers Squibb Company (BMY) Among The Top Dividend Contenders Right Now?

BMY

MT Newswires

6 days ago

JPMorgan Adjusts Price Target on Bristol-Myers Squibb to $70 From $64, Keeps Overweight Rating

BMY

MT Newswires

7 days ago

Daiwa Upgrades Bristol-Myers Squibb to Outperform From Neutral, Adjusts Price Target to $65 From $50

3 Stocks Seeing Insider Buys: CNC, PFE, BMY
BMY

Zacks

7 days ago

3 Stocks Seeing Insider Buys: CNC, PFE, BMY

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results
BMY

GlobeNewswire

7 days ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

BMY

MT Newswires

7 days ago

UBS Raises Bristol-Myers Squibb Price Target to $60 From $54, Maintains Neutral Rating

AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains
BMY

Zacks

7 days ago

AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains

BMY

MT Newswires

7 days ago

Goldman Sachs Adjusts Bristol-Myers Squibb Price Target to $65 From $62, Maintains Buy Rating

BMY

MT Newswires

7 days ago

Leerink Partners Upgrades Bristol-Myers Squibb to Outperform From Market Perform, Adjusts Price Target to $73 From $55

What the NFL Draft Can Teach Investors About Big Pharma
BMY

The Wall Street Journal

7 days ago

What the NFL Draft Can Teach Investors About Big Pharma

BMY

MT Newswires

8 days ago

BMO Capital Adjusts Price Target on Bristol-Myers Squibb to $61 From $57, Keeps Market Perform Rating

BMY

MT Newswires

8 days ago

Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb to $39 From $36, Keeps Underweight Rating

BMY

MT Newswires

8 days ago

Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $53 From $50, Keeps Neutral Rating

BMY

Morningstar Research

8 days ago

Analyst Report: Bristol-Myers Squibb Company

Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake'
BMY

Investor's Business Daily

8 days ago

Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake'

AbbVie tumbles on drug test disappointment, Bristol-Myers gains
BMY

Yahoo Finance Video

8 days ago

AbbVie tumbles on drug test disappointment, Bristol-Myers gains

BMY

MT Newswires

8 days ago

Top Midday Gainers

Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell?
BMY

Zacks

8 days ago

Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell?

AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint
BMY

Investopedia

8 days ago

AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint

On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
BMY

BioPharma Dive

8 days ago

On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps.
BMY

Barrons.com

8 days ago

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps.

BMY

MT Newswires

8 days ago

Citigroup Adjusts Bristol-Myers Squibb Price Target to $60 From $55

Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails
BMY

Investor's Business Daily

8 days ago

Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails

BMY

Investing.com

8 days ago

AbbVie shares slip after schizophrenia drug trial misses primary endpoint

BMY

MT Newswires

8 days ago

Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $55 From $48

Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024
BMY

Business Wire

8 days ago

Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024

BMY

Morningstar Research

11 days ago

Analyst Report: Bristol-Myers Squibb Company

BMY

Argus Research

11 days ago

Technical Assessment: Bullish in the Intermediate-Term

Here's Why Bristol-Myers Squibb (NYSE:BMY) Can Manage Its Debt Responsibly
BMY

Simply Wall St.

13 days ago

Here's Why Bristol-Myers Squibb (NYSE:BMY) Can Manage Its Debt Responsibly

Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
BMY

Zacks

13 days ago

Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know

Bristol Myers Squibb to Participate in Upcoming Investor Conferences
BMY

Business Wire

14 days ago

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy Right Now?
BMY

Insider Monkey

15 days ago

Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy Right Now?

Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade
BMY

Investor's Business Daily

18 days ago

Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade

BMY

MT Newswires

18 days ago

Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $62 From $60

BMY

MT Newswires

18 days ago

JPMorgan Chase Adjusts Price Target on Bristol-Myers Squibb to $64 From $60

BMY

MT Newswires

18 days ago

BMO Capital Adjusts Price Target on Bristol-Myers Squibb to $57 From $53

Company News for Nov 1, 2024
BMY

Zacks

18 days ago

Company News for Nov 1, 2024

BMY

MT Newswires

19 days ago

Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $36 From $37, Keeps Underweight Rating

Bristol-Myers Squibb Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
BMY

Simply Wall St.

19 days ago

Bristol-Myers Squibb Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Bristol-Myers Squibb Co (BMY) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic ...
BMY

GuruFocus.com

19 days ago

Bristol-Myers Squibb Co (BMY) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic ...

BMY

Thomson Reuters StreetEvents

19 days ago

Q3 2024 Bristol-Myers Squibb Co Earnings Call

Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)
BMY

GuruFocus.com

19 days ago

Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)

Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
BMY

Business Wire

19 days ago

Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024

Bristol Myers Screams To A Year-High After Walloping Profit Expectations
BMY

Investor's Business Daily

19 days ago

Bristol Myers Screams To A Year-High After Walloping Profit Expectations

A promising schizophrenia drug showed mixed results. What does that mean for patients?
BMY

Associated Press Finance

19 days ago

A promising schizophrenia drug showed mixed results. What does that mean for patients?

BMY

Morningstar Research

19 days ago

Analyst Report: Bristol-Myers Squibb Company

Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript
BMY

Motley Fool

19 days ago

Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript

Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View
BMY

Zacks

19 days ago

Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View

Bristol Myers Squibb stock rises, Merck moves lower. Here's why.
BMY

Yahoo Finance Video

19 days ago

Bristol Myers Squibb stock rises, Merck moves lower. Here's why.

Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit
BMY

Benzinga

19 days ago

Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit

BMY

MT Newswires

19 days ago

Sector Update: Health Care Stocks Lower to Flat Premarket Thursday

BMY

MT Newswires

19 days ago

Sector Update: Health Care

Bristol Myers Stock Rises. The Drugmaker Hiked Guidance After Sales Beat.
BMY

Barrons.com

19 days ago

Bristol Myers Stock Rises. The Drugmaker Hiked Guidance After Sales Beat.

Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates
BMY

Zacks

19 days ago

Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates

BMY

MT Newswires

19 days ago

Bristol-Myers Squibb Q3 Non-GAAP Earnings Fall, Revenue Rises; 2024 EPS Guidance Lifted

BMY

Investing.com

19 days ago

Bristol-Myers hikes annual earnings guidance as Q3 exceeds expectations; shares up

Bristol Myers Q3 earnings beat expectations, helped by sales of older drugs
BMY

Reuters

19 days ago

Bristol Myers Q3 earnings beat expectations, helped by sales of older drugs

Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance
BMY

Investor's Business Daily

19 days ago

Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance

Jim Cramer Says Bristol-Myers Squibb Company (BMY) Is ‘Too Low’
BMY

Insider Monkey

21 days ago

Jim Cramer Says Bristol-Myers Squibb Company (BMY) Is ‘Too Low’

Pfizer raises full-year guidance by $1.5 billion amid activist investor pressure
BMY

Yahoo Finance

21 days ago

Pfizer raises full-year guidance by $1.5 billion amid activist investor pressure

Should Bristol Myers Stock Be in Your Portfolio Pre-Q3 Earnings?
BMY

Zacks

22 days ago

Should Bristol Myers Stock Be in Your Portfolio Pre-Q3 Earnings?

Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?
BMY

Zacks

22 days ago

Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?

Curious about Bristol Myers (BMY) Q3 Performance? Explore Wall Street Estimates for Key Metrics
BMY

Zacks

22 days ago

Curious about Bristol Myers (BMY) Q3 Performance? Explore Wall Street Estimates for Key Metrics

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
BMY

Business Wire

23 days ago

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024

Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t
BMY

The Wall Street Journal

25 days ago

Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t

BMY

MT Newswires

25 days ago

Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $48 From $45

BMY

MT Newswires

a month ago

Citigroup Downgrades Bristol-Myers Squibb to Neutral From Buy, Adjusts Price Target to $55 From $75

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
BMY

Zacks

a month ago

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
BMY

Zacks

a month ago

Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for

Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
BMY

Zacks

a month ago

Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock

BMY

MT Newswires

a month ago

Redwire Collaborating With Bristol-Myers to Study Model Small Molecule Compounds in Space

BMY

MT Newswires

a month ago

Evotec to Receive $50 Million Payment Under Bristol Myers Squibb Partnership

Bristol Myers (BMY) Upgraded to Buy: Here's What You Should Know
BMY

Zacks

a month ago

Bristol Myers (BMY) Upgraded to Buy: Here's What You Should Know

BMY or VRTX: Which Is the Better Value Stock Right Now?
BMY

Zacks

a month ago

BMY or VRTX: Which Is the Better Value Stock Right Now?

BMY

MT Newswires

a month ago

Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $60 From $57

Bristol-Myers Squibb (BMY): Growth Potential Amid Strategic Acquisitions and Revenue Increase
BMY

Insider Monkey

a month ago

Bristol-Myers Squibb (BMY): Growth Potential Amid Strategic Acquisitions and Revenue Increase

Bristol Myers Squibb (BMY) Dips More Than Broader Market: What You Should Know
BMY

Zacks

a month ago

Bristol Myers Squibb (BMY) Dips More Than Broader Market: What You Should Know

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
BMY

Benzinga

a month ago

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

Bristol-Myers Squibb Company (BMY): A Bull Case Theory
BMY

Insider Monkey

a month ago

Bristol-Myers Squibb Company (BMY): A Bull Case Theory

BMY

MT Newswires

a month ago

Bernstein Initiates Coverage on Bristol-Myers Squibb With Market Perform Rating, $56 Price Target

Wave Life Sciences (WVE) Moves 74.1% Higher: Will This Strength Last?
BMY

Zacks

a month ago

Wave Life Sciences (WVE) Moves 74.1% Higher: Will This Strength Last?

Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.
BMY

Investor's Business Daily

a month ago

Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.

Share on Social Networks: